Investigating the Application of Liposomes as Drug Delivery Systems for the Diagnosis and Treatment of Cancer

Table 1

Liposomes functionalized with specific targeting ligands through various surface engineering techniques for the treatment of solid tumours.

Targeting ligand used	Surface modification method	Anticancer drug	Target tumour treated	Year
CA-IX antibody [51]	Coupling of DSPE-PEG-MAL micelles with DTT reduced antibodies was achieved via incubation for twenty-four hours at room temperature. DSPE-PEG-MAL-Ab micelles produced CA-IX directed liposomes by incubation at 60°C with preformed liposomes for two hours.	Docetaxel	Lung cancer	2014
Anti-HER2 antibody [52]	Terminal MAL group on liposomal surface conjugated to the thiol group	Doxorubicin	Breast cancer	2002
Anti-VEGFR2 [53]	Coincubation incorporated Fab’-Mal-PEG-DSPE into preformed liposomes for half an hour at 55°C succeeded by gel filtration purification	Doxorubicin	Colon cancer	2012
Anti-EGFR antibody [54]	The MAL group at the terminal end of DSPE-PEG-MAL preformed liposome chains was conjugated to thiolated antibody via incubation overnight with mild shaking at a temperature of 4°C	Small interfering RNA	Lung cancer	2015